Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.58 |
| ▸ | CNR2 | P34972 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743123 | 0.83 | CNR1 (0.68) | CNR1CNR2KDM4EGAASLC2A1 | |
| SCHEMBL18039524 | 0.81 | CNR1 (0.66) | CNR1CNR2KDM4EGAASLC2A1 | |
| SCHEMBL4324403 | 0.81 | CNR1 (0.60) | CNR1CNR2KDM4EGAASLC2A1 | |
| SCHEMBL4461480 | 0.79 | CNR1 (0.69) | CNR1CNR2KDM4EGAAHPGD | |
| SCHEMBL4341215 | 0.76 | CNR1 (0.62) | CNR1CNR2HPGD | |
| SCHEMBL4321329 | 0.76 | CNR1 (0.61) | CNR1CNR2KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL4326889 | 0.76 | CNR1 (0.70) | CNR1CNR2KDM4EGAASLC2A1 | |
| SCHEMBL4334526 | 0.76 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL4323115 | 0.76 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL3058529 | 0.76 | CNR1 (0.66) | CNR1CNR2GAASLC2A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2203171-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009025785-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009025785-A2 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004222-A1 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885KDM4E 3320/4885 |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885KDM4E 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.